Back to Blog
Kite pharma investor presentation7/25/2023 ![]() Their stock opened with 17.00 in its IPO. Kite Pharma is registered under the ticker NASDAQ:KITE. Their latest funding was raised on from a Post-IPO Equity round. For these years, our CSR reporting was incorporated into our Annual Report. Kite Pharma has raised a total of 335.4M in funding over 5 rounds. ![]() For previous years’ reports, please see Archive below.Īnnual Report 2015 (PDF) Sustainability / CSR reportsįrom 2018-2020, we did not publish a separate Sustainability or CSR report. Positive Phase 2 data for Anti IL-22R, an anti-inflammatory monoclonal antibody for atopic dermatitis, progressing to Phase 2B.įor 2023 we have set out to return to profit (EBITDA), while still delivering an operating loss.įor more information about our 2022 performance, read our Annual Report 2022 and Sustainability Report 2022.Matt Richtel and Andrew Pollack explore the complex policy issues involved with the pricing of products based on taxpayer-funded inventions and research in a front page New York Times story published today. ![]()
0 Comments
Read More
Leave a Reply. |